Dejenie Shiferaw, Abebe Aseffa, Melese Hailu Legese, Tesfaye Legesse, Hiwot Ketema and Kassu Desta
Ethiopian Public Health Institute, Ethiopia
Posters & Accepted Abstracts: J Infec Dis Treat
The global emergence and spread of extended-spectrum betalactamases (ESBLs) producing Enterobacteriaceae have been threatening the ability to treat infection. Hence, this study aimed to determine the prevalence of ESBL producing and multi-drug resistant (MDR) Enterobacteriaceae (ESBLs-E) from different clinical specimens in Addis Ababa, Ethiopia. A cross-sectional study was conducted from January 1st to May 30th, 2017 at EPHI. Identification and antimicrobial susceptibility testing (on Muller Hinton agar) was performed on 426 Enterobacteriaceae isolates. All Enterobacteriaceae were screened for ESBLs production using cefotaxime and ceftazidime as per CLSI guideline. ESBLs specious Enterobacteriaceae were confirmed by combination disk test (CDT). Data was entered and analyzed by using SPSS V. 20. The most frequent Enterobacteriaceae were E. coli–228 (53.5%) and K. pneumoniae–103 (24.1 %). The magnitude of ESBLs-E was 246 (57.7%). The highest frequencies of ESBLs-E were observed in blood specimen (84.4%) and the highest ESBLs production was observed in K. pneumoniae (85.4%). Highest resistance level was seen to sulfamethoxazole-trimethoprim (77.0%), augumentin (71.6%), cefotaxime (62.2%), cefepime (60.3) and ceftazidime (60.8%). The resistance to meropenem, amikacin and cefoxitin were 5.2%, 13.8% and 25.1%, respectively. The overall magnitude of MDR level was 68.3%. Of ESBLs-E, 96.3% of them were MDR (P < 0.001). There was a high prevalence of ESBLs-E and MDR isolate in Addis Ababa. Most of ESBLs-E were isolated primarily in blood and urine. The highest ESBLs production was observed among K. pneumoniae.
E-mail:
dejenie21@gmail.com
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 